Description of health covariates and pollutants for the total population and then defined by the level of control
| All | Controlled | Partly controlled | Uncontrolled | |
| n (%) | 481 (100) | 216 (44.9) | 144 (29.9) | 121 (25.2) |
| General characteristics* | ||||
| Females, N (%) | 239 (49.7) | 103 (47.7) | 64 (44.4) | 72 (59.5) |
| Age, mean (SD) | 39.5 (16.5) | 36.9 (15.5) | 40.7 (17.1) | 42.9 (16.7) |
| BMI, mean (SD) | 24.4 (4.5) | 24.1 (4.2) | 24.4 (4.8) | 25.1 (4.6) |
| Educational level* | ||||
| Primary, N (%) | 105 (22.2) | 43 (19.9) | 33 (23.4) | 29 (25.0) |
| Secondary, N (%) | 132 (27.9) | 67 (31.0) | 31 (22.0) | 34 (29.3) |
| University, N (%) | 236 (49.9) | 106 (49.1) | 77 (54.6) | 53 (45.7) |
| Active/passive smoking status* | ||||
| Non-smoking and ETS−, N (%) | 268 (55.7) | 115 (53.2) | 83 (57.4) | 70 (57.9) |
| Non-smoking and ETS+, N (%) | 88 (13.3) | 39 (18.1) | 30 (20.8) | 19 (15.7) |
| Current smoking, N (%) | 125 (26.0) | 62 (28.7) | 31 (21.5) | 32 (26.4) |
| Clinical characteristics | ||||
| Age of onset of asthma ≤16*, N (%) | 297 (65) | 140 (69) | 88 (63) | 69 (61) |
| Atopy†, N (%) | 355 (80.5) | 162 (79.0) | 106 (80.9) | 87 (82.9) |
| FEV1 <80% predicted†, N (%) | 78 (16.6) | 0 (0) | 39 (28.1) | 39 (33.6) |
| IgE >100 UI/ml†, N (%) | 288 (61.5) | 114 (53.5) | 97 (69.8) | 77 (66.3) |
| BHR† | 188 (69.4) | 106 (65.8) | 48 (73.9) | 34 (75.6) |
| At least one symptom*, N (%) | 177 (36.8) | 0 (0) | 85 (59.0) | 92 (76.0) |
| Exacerbations*, N (%) | 79 (16.5) | 0 (0) | 0 (0) | 79 (65.3) |
| ICS*, N (%) | 241 (50.1) | 68 (31.5) | 85 (59.0) | 88 (72.7) |
| Air pollutants in μg/m3‡ | ||||
| NO2, mean (min–max) | 32.1 (7.7–50.2) | 32.9 (7.7–50.2) | 31.2 (8.8–50.2) | 31.9 (11.4–50.2) |
| O3-an, mean (min–max) | 47.3 (35.7–74.1) | 46.3 (35.7–66.7) | 48.3 (35.7–74.1) | 47.9 (35.7–68.1) |
| O3-sum, mean (min–max) | 67.1 (52.4–86.3) | 65.9 (54.4–80.8) | 67.7 (52.4–86.3) | 69.8 (55.4–78.9) |
| PM10, mean (min–max) | 20.2 (12.2–27.6) | 19.8 (12.2–27.6) | 20.3 (12.2–27.2) | 21.0 (1.44–27.6) |
Educational level: based on highest diploma; Atopy: at least one weal ≥3 mm to 11 tested allergens; BHR: pd20<4 mg of metacholine; At least one symptom: >1 diurnal symptom per week or an asthma attack in the past 3 months or a nocturnal symptom in the past 3 months; Exacerbations: at least one hospitalisation or emergency room visit or one course of oral corticosteroids in the last year; ICS: use of inhaled corticosteroids in the past 12 months.
↵* Collected through questionnaire.
↵† Objectively measured in a hospital setting.
↵‡ Modelled at each subject's address.
BHR, bronchial hyperresponsiveness; BMI, body mass index; ETS, environmental tobacco smoke.